Should I Order an ANA?

A positive ANA (antinuclear antibody) means the immune system has produced antibodies against the cell nucleus — but it does not mean the patient has an autoimmune disease. Up to 20% of healthy people have a positive ANA at 1:80 dilution. The clinical significance depends entirely on the titer (1:80 is weak, 1:640 is much more meaningful), the pattern (homogeneous, speckled, nucleolar), and the presence of clinical symptoms. A positive ANA in an asymptomatic patient with no systemic features rarely requires further investigation.

As a general rule: 1:80 is weakly positive and found in up to 20% of healthy people. 1:160 is more significant and warrants clinical correlation. 1:320 and above is strongly positive and raises genuine concern for autoimmune disease, especially when symptoms are present. Titer alone should never be used to make a diagnosis — a 1:640 ANA in an asymptomatic person still needs clinical context, while a 1:80 ANA in a patient with malar rash, cytopenias, and joint pain is highly clinically relevant.

Common causes of a false positive ANA include: older age (ANA positivity increases with age), certain medications (hydralazine, procainamide, isoniazid, minocycline), infections (EBV, hepatitis C, parvovirus), chronic liver disease, and simply being female. The most common reason for a false positive ANA is ordering the test in a patient with a low pre-test probability for autoimmune disease. This is why this tool assesses clinical features before recommending ANA testing.

The ANA pattern describes how the antibodies bind within the cell nucleus, and different patterns are associated with different diseases. Homogeneous (diffuse) pattern is associated with SLE and drug-induced lupus. Speckled pattern is the most common and least specific, but can indicate anti-SSA/SSB (Sjögren's), anti-Sm, or anti-RNP. Nucleolar pattern is associated with systemic sclerosis (scleroderma). Centromere pattern is strongly associated with limited systemic sclerosis (CREST syndrome). The pattern guides which reflex antibodies to order next.

ENA (extractable nuclear antigens) testing is ordered when the ANA is positive and there is reasonable clinical suspicion for a specific connective tissue disease. You should not reflexively order a full ENA panel on every positive ANA. Instead, let the clinical picture guide which antibodies to order: suspected SLE → anti-dsDNA and anti-Sm; suspected Sjögren's → anti-SSA (Ro) and anti-SSB (La); suspected scleroderma → anti-Scl-70 and anti-centromere; suspected mixed CTD → anti-RNP. Most labs now offer a targeted approach.

ANA-negative lupus is rare but exists — approximately 2–5% of SLE patients are ANA-negative by standard testing. If clinical suspicion for lupus is high, a negative ANA should not definitively exclude the diagnosis. Consider testing anti-dsDNA, anti-Sm, and complement C3/C4 directly, and refer to rheumatology. ANA-negative lupus is more commonly seronegative on HEp-2 cell substrate testing but may be positive with alternative substrates.